home / stock / tpst / tpst news

TPST News and Press, Tempest Therapeutics Inc. From 04/21/25

Stock Information
Company Name: Tempest Therapeutics Inc.
Stock Symbol: TPST
Market: NASDAQ
Website: tempesttx.com
Menu
TPST TPST Quote TPST Short TPST News TPST Articles TPST Message Board
Get TPST Alerts

News, Short Squeeze, Breakout and More Instantly...
TPST - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has gr...
TPST - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in place Awarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in...

TPST - TPST announced stock split 1-13

2025-04-09 09:01:19 ET Tempest Therapeutics, Inc. (TPST) announced stock split at a ratio of 1-for-13 on 2025-04-09 ... Full story available on KlickAnalytics.com

TPST - Tempest Therapeutics GAAP EPS of -$1.50 misses by $0.15

2025-03-27 16:52:13 ET More on Tempest Therapeutics Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Therapeutics Read the full article on Seeking Alpha For...
TPST - Tempest Reports Year End 2024 Financial Results and Provides Business Update

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial ...

TPST - Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an abstract highlighting data supporting the immun...

TPST - Expected US Company Earnings on Tuesday, March 25th, 2025

Cadeler A/S American Depositary Share (each representing four (4) Ordinary Shares) (CDLR) is expected to report $0.34 for Q4 2024 China Mengniu Dairy Company Limited ADR (CIADY) is expected to report for Q4 2024 Atossa Therapeutics Inc. (ATOS) is expected to report $-0.06 for Q4 2024 ...
TPST - Expected US Company Earnings on Tuesday, March 18th, 2025

Gritstone bio Inc. (GRTS) is expected to report for Q4 2024 OneConnect Financial Technology Co. Ltd. American Depositary Shares each representing thirty (OCFT) is expected to report for quarter end 2024-12-31 2seventy bio Inc. (TSVT) is expected to report $-0.2 for Q4 2024 CorMedix In...

TPST - FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer Prevention Clinical Trials Network rece...

TPST - Tempest gets fast track designation from FDA for amezalpat

2025-02-10 08:26:35 ET More on Tempest Therapeutics Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Therapeutics Read the full article on Seeking Alpha For...
Previous 10 Next 10